×
About 11,708 results

ALLMedicine™ Parkinson Disease Center

Research & Reviews  4,047 results

Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease-Reply.
https://doi.org/10.1001/jamaneurol.2022.1604
JAMA Neurology; Gray R, Jenkinson C et. al.

Jun 28th, 2022 - Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease-Reply.|2022|Gray R,Jenkinson C,Clarke CE,|

Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease.
https://doi.org/10.1001/jamaneurol.2022.1601
JAMA Neurology; Gros P, Fox SH et. al.

Jun 28th, 2022 - Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease.|2022|Gros P,Fox SH,Lang AE,|

The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.
https://doi.org/10.1038/s41582-022-00681-2 10.1016/S1474-4422(19)30195-4 10.1016/S0140-6736(21)00218-X 10.1007/s11940-018-0539-9 10.1056/NEJMra1600266 10.1016/S1474-4422(19)30356-4 10.1016/j.chom.2020.06.008 10.1038/d41586-021-00260-3 10.1002/ana.25982 10.1007/BF00687767 10.1016/S0197-4580(02)00065-9 10.1002/mds.27556 10.1038/nrneurol.2015.197 10.1093/brain/awaa238 10.1136/jnnp-2015-311680 10.1002/mds.28636 10.1212/WNL.0000000000003961 10.1002/ana.24448 10.1016/j.tins.2016.10.008 10.1002/ana.24531 10.1016/S1474-4422(18)30162-5 10.1007/s00401-013-1214-6 10.1002/mds.25020 10.1002/ana.24648 10.1007/s00401-010-0664-3 10.1007/s00401-020-02233-8 10.3233/JPD-212733 10.1007/s00401-019-02040-w 10.3233/JPD-191703 10.1002/mds.27794 10.1007/s00401-012-1040-2 10.1007/s00401-014-1343-6 10.1016/j.neuron.2019.05.035 10.1038/s41593-020-0589-7 10.1093/brain/awab061 10.1186/s40035-019-0146-z 10.1186/s13024-021-00439-2 10.1038/srep34477 10.7554/eLife.53111 10.1111/nmo.13777 10.1007/s00401-016-1661-y 10.1136/gutjnl-2012-302550 10.1093/brain/awaa096 10.1038/s41380-019-0608-9 10.1186/s12974-016-0608-5 10.1111/nmo.13726 10.1007/s00401-017-1777-8 10.1371/journal.pone.0028032 10.1002/mds.25736 10.1186/s40478-015-0196-0 10.1002/mds.27326 10.1016/j.parkreldis.2018.02.022 10.1136/gutjnl-2018-316844 10.1038/s41575-019-0261-4 10.1016/j.bbi.2019.06.042 10.1016/j.nbd.2012.09.007 10.1111/jnc.12742 10.3390/ijms21239199 10.14802/jmd.21085 10.1038/s41582-020-0344-4 10.1038/s41531-016-0002-0 10.1159/000477990 10.3233/JPD-140491 10.1073/pnas.1610099113 10.2147/JIR.S196552 10.1002/mds.23838 10.1007/s00401-018-1943-7 10.1172/jci.insight.92295 10.1016/j.cell.2016.11.018 10.1038/s41586-019-1405-y 10.1016/j.parkreldis.2016.08.019 10.1007/s00415-019-09321-0 10.1080/17474124.2017.1343143 10.1016/j.tim.2017.11.002 10.1038/nri.2017.7 10.1016/j.cell.2019.12.025 10.1016/j.cell.2018.02.044 10.1038/nature12820 10.1038/nature11053 10.1126/science.aad3503 10.1038/nature25979 10.1053/j.gastro.2020.09.057 10.1016/j.chom.2020.07.013 10.1016/j.cell.2017.11.024 10.1038/nature11319 10.1038/s41574-018-0059-4 10.1016/j.chom.2017.03.002 10.1038/ismej.2015.88 10.1016/j.cub.2016.08.015 10.1016/j.mad.2019.02.001 10.1128/mSystems.00325-19 10.1128/mSystems.00124-20 10.3233/JPD-202237 10.1186/s13073-017-0428-y 10.1002/mds.26942 10.1002/mds.28052 10.1002/mds.28119 10.1002/mds.27581 10.1038/s41531-021-00156-z 10.1016/j.parkreldis.2021.11.017 10.1186/s12915-020-00775-7 10.1038/s41531-020-0112-6 10.1093/brain/awaa201 10.1002/jgh3.12450 10.1136/gutjnl-2018-316723 10.1016/j.parkreldis.2018.06.020 10.1016/j.parkreldis.2020.06.015 10.1038/s41467-017-01973-8 10.1038/s41587-020-0603-3 10.1128/mSystems.00561-20 10.1186/s13024-021-00427-6 10.1038/s41575-019-0157-3 10.1016/j.bbr.2015.05.052 10.1016/j.neuropharm.2012.01.026 10.1016/j.jnutbio.2019.03.021 10.1002/mds.27203 10.1016/j.celrep.2021.108807 10.18632/aging.102221 10.1016/j.neuro.2019.11.009 10.1021/acschemneuro.0c00475 10.1007/s11064-018-2620-x 10.1080/19490976.2020.1866974 10.3920/BM2017.0202 10.3389/fnagi.2017.00441 10.1016/j.nbd.2018.12.012 10.1016/j.neuro.2018.02.013 10.1371/journal.pone.0217194 10.1016/j.expneurol.2019.113159 10.1111/jnc.14299 10.3389/fnins.2019.01032 10.1016/j.neuro.2019.09.004 10.1016/j.bbi.2018.02.005 10.1038/nn.4030 10.3748/wjg.v21.i37.10609 10.1016/j.celrep.2019.12.078 10.1093/femsre/fuv036 10.1212/WNL.57.3.456 10.1016/j.cgh.2020.08.059 10.1038/s41531-021-00191-w 10.1016/j.parkreldis.2020.01.009 10.1016/j.cell.2009.09.033 10.1097/MIB.0000000000000714 10.1001/jamaneurol.2018.0605 10.1016/j.dld.2018.09.017 10.1212/WNL.0000000000011630 10.1002/mds.28594 10.1038/s41531-021-00170-1 10.1126/scitranslmed.aai7795 10.1001/jamaneurol.2017.0469 10.1002/mds.28890 10.1038/s41575-020-0286-8 10.3233/JPD-202330 10.1007/s10654-014-9878-3 10.1136/gutjnl-2018-316937 10.1007/s00415-021-10688-2 10.1038/s41531-020-00145-8 10.1002/ana.24518 10.1126/scitranslmed.aar5280 10.1002/mds.28553 10.3389/fneur.2020.00510 10.1002/mds.26670 10.1002/mds.26761 10.1002/mds.109 10.3390/metabo11010029 10.1053/j.gastro.2019.02.036 10.14309/ajg.0000000000000501 10.1111/j.1468-1331.2011.03643.x 10.1016/j.parkreldis.2017.11.331 10.1016/j.parkreldis.2014.12.009 10.1007/s00415-013-7089-6 10.1016/j.gtc.2017.09.008 10.1016/j.parkreldis.2014.02.019 10.1007/s00702-016-1612-8 10.1002/mds.22190 10.1002/mds.25522 10.1212/01.wnl.0000221672.01272.ba 10.3233/JPD-181327 10.1371/journal.pone.0153725 10.1001/jamaneurol.2017.1125 10.1002/mds.27105 10.1128/mSystems.00797-20 10.1002/ana.25788 10.1007/s00415-019-09320-1 10.3390/biom11020144 10.1002/mds.26069 10.3233/JPD-202297 10.1371/journal.pone.0187307 10.1016/j.ebiom.2019.05.064 10.1002/mds.28016 10.3233/JPD-212604 10.1212/WNL.0000000000013225 10.3390/nu10101398 10.1016/j.nut.2020.111090 10.1016/j.cca.2019.10.038 10.1002/mds.28246 10.1126/science.aau5812 10.1038/s41575-018-0061-2 10.3390/nu11081896 10.1111/ggi.12321 10.1002/iub.1428 10.1002/mds.28173 10.1212/WNL.0000000000011373 10.1002/mds.27120 10.1002/mds.26819 10.1016/j.clnu.2021.05.011 10.1159/000355849 10.1212/01.wnl.0000225050.57553.6d 10.1017/S0007114510001005 10.3390/nu7095333 10.1093/aje/kwh213 10.1002/acn3.51227 10.1016/j.neurobiolaging.2021.06.023 10.1002/mds.27301 10.3233/JPD-181535 10.1007/s10072-015-2349-0 10.1002/mds.25076 10.1111/ggi.12123 10.1016/j.parkreldis.2020.10.024 10.3390/nu13010088 10.1002/ana.24385 10.1212/WNL.0b013e31824f7fc4 10.1212/WNL.0000000000002351 10.1093/aje/kwm385 10.1212/WNL.0000000000008191 10.1212/WNL.0000000000004057 10.1007/s10654-014-9921-4 10.1007/s00415-018-9032-3 10.1002/mds.28039 10.1002/mds.27933 10.1016/j.parkreldis.2019.12.006 10.1136/jnnp-2020-323646 10.1002/mds.27577 10.1093/ajcn/86.5.1486 10.1002/mds.28314 10.1002/mds.27489 10.1002/mds.24918 10.1002/mds.28464 10.1016/j.parkreldis.2017.06.007 10.1093/gerona/glx227 10.1038/s41579-019-0256-8 10.1002/mds.28411 10.4049/jimmunol.1000548 10.1038/s41531-017-0010-8 10.1126/scitranslmed.aan8162 10.1002/mds.28347 10.1038/s41531-021-00218-2 10.1016/j.parkreldis.2020.08.015 10.1016/j.parkreldis.2018.06.003 10.1016/j.parkreldis.2020.05.001 10.1517/14656566.2015.1086747 10.1002/mds.28219 10.1002/mds.27259 10.1016/j.clinthera.2020.04.004 10.1126/scitranslmed.aad8858 10.1097/00002826-198712000-00004 10.1212/WNL.0000000000007173 10.1002/mds.28248 10.1097/00002826-199210000-00004 10.1126/science.aau6323 10.1038/s41467-019-08294-y 10.1038/s41582-019-0145-9 10.1093/brain/aws086 10.1136/bmjgast-2017-000132 10.1111/jgs.13675 10.1016/j.jocd.2020.07.001 10.1186/s40734-016-0036-9 10.1126/science.aat9931 10.1038/s41586-019-1291-3 10.1016/j.cell.2020.05.001 10.1016/j.parkreldis.2018.04.003 10.1016/S1474-4422(15)00007-1 10.1097/WNF.0000000000000037 10.1038/s41575-019-0173-3 10.1038/s41591-019-0439-x 10.1126/scitranslmed.aaw1815 10.1001/jama.2019.19602 10.1002/mds.27390 10.3390/cells9020376 10.1212/WNL.0000000000004568 10.1016/j.gpb.2021.08.009 10.1212/WNL.0000000000003127 10.1212/WNL.0000000000011652 10.1016/j.clineuro.2021.106791 10.1186/s12934-021-01589-0 10.1053/j.gastro.2019.07.025 10.1016/j.prdoa.2019.06.001 10.1038/s41575-019-0204-0
Nature Reviews. Neurology; Tan AH, Lim SY et. al.

Jun 25th, 2022 - Evidence for a close bidirectional link between the brain and the gut has led to a paradigm shift in neurology, especially in the case of Parkinson disease (PD), in which gastrointestinal dysfunction is a prominent feature. Over the past decade, n...

Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
https://clinicaltrials.gov/ct2/show/NCT00302146

Jun 24th, 2022 - An association between Gaucher disease and parkinsonism has been demonstrated by the concurrence of parkinsonian manifestations in patients with Gaucher disease and an increased incidence of glucocerebrosidase (GBA) mutations in subjects with park...

Genetic Studies of Lysosomal Storage Disorders
https://clinicaltrials.gov/ct2/show/NCT00001215

Jun 24th, 2022 - There is a vast spectrum of clinical manifestations encountered in individuals with lysosomal storage diseases. Lysosomal storage disorders occur when an enzyme necessary for breaking down intracellular fats, proteins, recycled products and organe...

see more →

Guidelines  1 results

Physical Therapist Management of Parkinson Disease: A Clinical Practice Guideline From ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046970
Physical Therapy; Osborne JA, Botkin R et. al.

Dec 29th, 2021 - A clinical practice guideline on Parkinson disease was developed by an American Physical Therapy Association volunteer guideline development group that consisted of physical therapists and a neurologist. The guideline was based on systematic revie...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  389 results

Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
https://clinicaltrials.gov/ct2/show/NCT00302146

Jun 24th, 2022 - An association between Gaucher disease and parkinsonism has been demonstrated by the concurrence of parkinsonian manifestations in patients with Gaucher disease and an increased incidence of glucocerebrosidase (GBA) mutations in subjects with park...

Imaging Biomarkers in Parkinson s Disease
https://clinicaltrials.gov/ct2/show/NCT01496599

Jun 24th, 2022 - Objectives: The purpose of this protocol is to evaluate possible imaging biomarkers for diagnosis and assessment of disease progression in Parkinson disease (PD) through multi-modal neuroimaging studies. The study will have two parts: Part 1: Comp...

Genetic Studies of Lysosomal Storage Disorders
https://clinicaltrials.gov/ct2/show/NCT00001215

Jun 24th, 2022 - There is a vast spectrum of clinical manifestations encountered in individuals with lysosomal storage diseases. Lysosomal storage disorders occur when an enzyme necessary for breaking down intracellular fats, proteins, recycled products and organe...

Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease
https://clinicaltrials.gov/ct2/show/NCT05421624

Jun 16th, 2022 - Parkinson disease (PD) is the fastest growing source of disability among neurological disorders. Diminished physical activity is highly prevalent in PD and often lead to the onset of disability. Regular, habitual exercise is a critical component o...

Istradefylline for Parkinson Disease With Cognitive Impairment
https://clinicaltrials.gov/ct2/show/NCT05333549

Jun 15th, 2022 - Istradefylline has been approved by the U. S. Food and Drug Administration (FDA) to reduce "off" episodes in Parkinson disease. The period when levodopa has a positive effect on Parkinson's symptoms is called on-time. Once the medication stops wor...

see more →

News  236 results

Don’t overlook this cause of falls
https://www.mdedge.com/familymedicine/article/255459/geriatrics
MDedge Family Medicine; Ernestine Lee, MD, MPH

Jun 15th, 2022 - I enjoyed reading “How to identify balance disorders and reduce fall risk” (J Fam Pract. 2022;71:20-30) from the January/February issue.

Lithium Linked to Dementia Prevention
https://www.medpagetoday.com/psychiatry/dementia/97725

Mar 17th, 2022 - Treatment with lithium may be protective against dementia and its subtypes, a retrospective cohort study indicated. Among patients receiving mental health care, those exposed to lithium at standard clinical dosages had a 44% lower risk of receivin...

DMARDs or corticosteroids use may not explain reduced risk for Parkinson disease in RA
https://www.mdedge.com/rheumatology/article/252183/rheumatoid-arthritis/dmards-or-corticosteroids-use-may-not-explain

Feb 24th, 2022 - Key clinical point: The use of disease-modifying antirheumatic drugs (DMARD) or corticosteroids did not affect the risk for Parkinson's disease (PD) in patients with rheumatoid arthritis (RA), except for chloroquine/hydroxychloroquine, which may b.

Neurology Case Challenge: Visual and Auditory Hallucinations in a Patient With Parkinson Disease
https://www.medscape.com/viewarticle/736108

Jan 21st, 2022 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...

Survey identifies clinicians’ unease with genetic testing
https://www.mdedge.com/neurology/article/246396/parkinsons-disease/survey-identifies-clinicians-unease-genetic-testing
Richard Mark Kirkner

Sep 21st, 2021 - Before getting to work on developing guidelines for genetic testing in Parkinson’s disease, a task force of the Movement Disorders Society surveyed members worldwide to identify concerns they have about using genetic testing in practice. In result.

see more →

Patient Education  3 results see all →